This article was originally published in Start Up
Protometrix's microarray technology enables it to produce, purify, and assay thousands of proteins at once on a solid surface. With this skill set, the company believes it can become the first firm able to offer drug developers the ability to scan the entire human proteome in a high-throughput setting.
You may also be interested in...
A deluge of DNA sequence and gene expression data generated in the last five years encouraged the original high-throughput mentality within genomics companies. Mapping the human genome provided the impetus for developing technologies for high-throughput DNA sequencing and analysis. Now genotyping, or the detection and analysis of individual genetic variations, has become the newest market around which companies are preaching the need for high-throughput methodologies.While only a handful of companies were directly involved in assisting the Human Genome Project, genotyping--the detection and analysis of individual genetic variations--has been fueling technology development, with applications in basic research through drug development. But in genotyping, high throughput is the goal but is not yet the reality. On the other hand, even if it's early to be talking about the successful integration of genotyping technologies and data, current players are already pushing their technologies onto their customers' platforms. If a company isn't already a player, it may be too late.
A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.
A better understanding of heme trafficking could lead to drug targets in metabolic diseases, anemias, porphyrias, hemolytic diseases such as sickle cell disease – even parasitic infections.